AstraZeneca Q2 results beat estimates; COVID vaccine sales dry up
By Maggie Fick and Radhika Anilkumar LONDON (Reuters) -AstraZeneca on Friday delivered forecast-beating profits and sales in the second quarter as a strong performance by its blockbuster cancer drugs offset the loss of COVID-19 vaccine sales. Shares in the Anglo-Swedish drugmaker, which has a strong line-up of cancer, metabolic and rare disease drugs, rose as…
